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Introduction {#sec1}
============

Inactivating mutations in genes encoding components of the SWI/SNF chromatin remodeling complex are found in ∼20% of cancers ([@bib13]). Treatment of this class of tumors is challenging and there are currently no targeted therapies approved for clinical use. The prototypical example of this class is the malignant rhabdoid tumors (MRTs), which are rare pediatric cancers of the kidney and soft tissues. MRTs are characterized by the biallelic inactivation of the *SMARCB1* (*INI1/SNF5/BAF47*) gene, which encodes a core component of the SWI/SNF complex and is a tumor suppressor ([@bib15]).

In addition to the MRTs, atypical teratoid/rhabdoid tumors (AT/RTs) are rhabdoid tumors of the CNS that are similarly characterized by the loss of SMARCB1 ([@bib6]). MRTs are highly aggressive, and, despite intensive multimodal therapy, prognosis remains dismal with many children not surviving beyond 12 months ([@bib18]). SMARCB1 mutation is the sole driver of disease, and MRTs and AT/RTs lack additional gene amplifications or deletions and demonstrate low rates of mutations ([@bib3], [@bib11], [@bib16]). The mechanisms by which SMARCB1 loss contributes to tumor progression are not fully understood, and analyses of genes regulated by SMARCB1 have revealed several candidate oncogenes, including components of the cell cycle machinery, sonic hedgehog pathway, and canonical Wnt signaling ([@bib15]). Identifying the fundamental oncogenic drivers resulting from SMARCB1 deficiency remains a significant challenge and a key barrier to developing effective therapies.

Receptor tyrosine kinases (RTKs) are attractive targets for cancer therapy with several tyrosine kinase inhibitors (TKIs) clinically approved for a range of tumor types ([@bib17]). We and others have shown that cancer cells rely on the activation of multiple RTKs to maintain robust oncogenic signaling ([@bib9]). Employing TKI combinations is effective in overcoming compensatory RTK signaling and ultimately killing cancer cells ([@bib28]). In this study, we utilize an integrated molecular profiling and chemical biology approach to show that MRT cells display coactivation of PDGFRα and FGFR1 and that therapeutic inhibition of both RTKs leads to synergistic cytotoxicity. Our findings demonstrate that exploiting RTK coactivation dependencies may be beneficial in the treatment of cancers with SWI/SNF deficiencies.

Results {#sec2}
=======

MRT Cell Lines Are Selectively Responsive to Dasatinib, Pazopanib, and Sunitinib {#sec2.1}
--------------------------------------------------------------------------------

The TKIs dasatinib, pazopanib, and sunitinib are either approved or currently being evaluated for soft tissue malignancies, such as sarcomas and MRTs. To identify subtypes that may be selectively responsive to these TKIs, a panel of 14 sarcoma and MRT lines were subjected to dose-response assessment. Only the MRT cell lines A204 and G402 were found to be sensitive to all three TKIs ([Figure 1](#fig1){ref-type="fig"}A; [Table S1](#mmc1){ref-type="supplementary-material"}).

Analysis of Acquired Resistance Identifies PDGFRα as an Oncogenic Driver in MRT Cells {#sec2.2}
-------------------------------------------------------------------------------------

Durable responses to TKIs are rare and most patients develop acquired drug resistance ([@bib14]). To discover potential resistance mechanisms, we modeled acquired resistance in vitro by subjecting the A204 cells to long-term escalating dose treatment with each of the three TKIs. Cell viability analysis confirmed that these sublines have acquired resistance and were cross-resistant to each other ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"}), suggesting a common mechanism of action.

To identify candidate kinases that confer TKI sensitivity, we assessed the target selectivity overlap among the three inhibitors based on published screens of TKI selectivity ([@bib1], [@bib5]). Pazopanib, dasatinib, and sunitinib share three common RTK targets, KIT, CSF1R, and PDGFRα ([Figure 1](#fig1){ref-type="fig"}C), of which only PDGFRα is activated in the A204 cells as shown by a previous phosphoproteomic screen ([@bib2]). Immunoblotting revealed a reduction in PDGFRα expression in the acquired resistant sublines ([Figure 1](#fig1){ref-type="fig"}D), indicating that a loss in PDGFRα pathway dependency is a potential mechanism of drug resistance.

Treatment of the parental A204 cells with the three TKIs led to a decrease in PDGFRα phosphorylation ([Figure 1](#fig1){ref-type="fig"}E). Furthermore, small interfering RNA (siRNA) depletion of PDGFRα was able to phenocopy the TKI effects and decrease MRT cell viability ([Figures 1](#fig1){ref-type="fig"}F and 1G). Immunoblot analysis of downstream signaling components AKT and ERK1/2, which control cell proliferation and survival, showed that the TKIs abolished AKT phosphorylation but had no effect on ERK1/2 phosphorylation in the parental cells ([Figure 1](#fig1){ref-type="fig"}H). Upon ectopic expression of SMARCB1 in the MRT cells, PDGFRα levels were decreased compared to control ([Figure 1](#fig1){ref-type="fig"}I), demonstrating that SMARCB1 regulates PDGFRα expression. Collectively, our findings show that PDFGRα is a driver in MRT cells that is regulated by SMARCB1 and can be effectively inhibited using pazopanib, dasatinib, and sunitinib.

Molecular Profiling of A204 Parental and Resistant Cells {#sec2.3}
--------------------------------------------------------

To identify additional candidate drivers in MRTs, we undertook a molecular profiling strategy comprising microarray-based comparative genomic hybridization (aCGH), gene expression analysis, and phosphoproteomics, using the A204 parental and three resistant sublines as a model. The aCGH was performed to assess chromosomal gains or losses associated with acquired resistance. The A204 cells have a simple genome with no detectable chromosomal alterations other than a focal deletion of *SMARCB1* at 22q11.23 ([Figures 2](#fig2){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A), which is maintained in the resistant sublines. Of the resistant cells, only the dasatinib-resistant (DasR) subline harbored additional gains on chromosome 17q21.32-q25.3 and losses of the whole arm of 13q ([Figure 2](#fig2){ref-type="fig"}A). Since this genomic profile was specific to DasR, it is unlikely that any targets identified in these chromosomal regions would be common to all three TKIs and, thus, were not pursued further. Gene expression analysis of the four cell lines in the presence of TKI showed that the resistant sublines clustered together with the untreated parental cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B), and it confirmed that *PDGFRA* was among the most highly downregulated genes in the resistant cells ([Figures 2](#fig2){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C).

Phosphoproteomics was used to compare the signaling profiles of DasR and pazopanib-resistant (PazR) sublines versus parental cells. Sunitinib-resistant (SunR) cells were not analyzed because their low proliferation rate prevented sufficient cells from being harvested. We show that parental cells displayed high levels of phosphorylated PDGFRα at multiple sites (Y613, Y742, Y762, Y768, and Y849) ([Figure 2](#fig2){ref-type="fig"}C). Interestingly, FGFR1 phosphorylation in the kinase insert domain (Y583 and Y585) also was found to be elevated in the parental cells. Additionally, FGFR1 was phosphorylated in its activation loop (Y653 and Y654) at similar levels in both parental and resistant cells. These data confirm that PDGFRα is the only common kinase target of pazopanib, dasatinib, and sunitinib that is activated in these cells ([Figure 1](#fig1){ref-type="fig"}C), and they demonstrate that both PDGFRα and FGFR1 are coactivated with multiple phosphosites observed in each receptor.

Dual Targeting of PDGFRα and FGFR1 Enhances Apoptosis {#sec2.4}
-----------------------------------------------------

Since FGFR1 phosphorylation was uncovered in our phosphoproteomic analysis, coupled with a previous report that FGFR RTKs are therapeutic targets in MRTs ([@bib27]), we reasoned that a combination of PDGFRα and FGFR inhibitors may have enhanced efficacy. We first assessed the effects of two selective FGFR TKIs NVP-BGJ398 and AZD4547 on the viability of A204 and G402 cells ([@bib24]). AZD4547 was ineffective in both cell lines while BGJ398 only reduced viability in the A204 cells ([Figure 3](#fig3){ref-type="fig"}A). As a positive control, AN3CA cells that harbor an FGFR2 mutation and are sensitive to FGFR TKIs were used ([@bib24]). Depletion of FGFR1 using siRNA also showed a minor decrease in the viability of the MRT cells ([Figures 3](#fig3){ref-type="fig"}B and 3C).

We evaluated the effects of BGJ398 and AZD4547 in combination with PDGFRα TKIs on cell viability and apoptosis. This combination showed a small decrease in A204 and G402 viability compared to single inhibitor treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}A), reflecting the strong cytostatic consequence of PDGFRα TKI monotherapy ([Figure 1](#fig1){ref-type="fig"}A). Assessment of caspase 3/7 activity found that PDGFRα or FGFR TKI treatment alone led to low levels of apoptosis despite high drug concentrations of up to 1 μM ([Figures 3](#fig3){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B). Dual PDGFRα and FGFR inhibition showed significantly increased apoptosis (\>6-fold relative to vehicle control). This enhanced apoptosis was recapitulated with a combination of siRNA depletion of PDGFRα and BGJ398 or AZD4547 treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}C). To assess if the combination confers synergistic cytotoxicity in the A204 cells, we employed an automated imaging assay to visualize annexin V-positive cells. While the individual TKIs only resulted in \<5% apoptotic cells ([Figure S2](#mmc1){ref-type="supplementary-material"}D), the combination of BGJ398 with either pazopanib or dasatinib led to a synergistic increase (combination index \< 1) in the proportion of apoptotic cells to ∼30%--50% across all drug doses tested ([Figures 3](#fig3){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}D).

To establish if a dual inhibitor of both receptors is capable of inducing apoptosis as a single agent, the effects of ponatinib, a potent inhibitor of FGFR1 and PDGFRα ([@bib7]), were investigated. While previous reports claim that pazopanib and sunitinib are FGFR1 inhibitors, the K~D~ of these compounds for FGFR1 are 128-fold and 67-fold higher, respectively, compared to ponatinib ([@bib26]). Assessing the dose-response effects of ponatinib in the panel of 17 cell lines, consisting of five SMARCB1-deficient cell lines (A204, G402, G401, BT12, and CHLA226) and 12 wild-type sarcoma cell lines, confirmed that cells with SMARCB1 deficiency were sensitive to this TKI ([Figure 3](#fig3){ref-type="fig"}F). Treatment with ponatinib resulted in enhanced apoptosis in the A204 and G402 MRT cells, at levels similar to combined PDGFRα and FGFR TKI treatment ([Figures 3](#fig3){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}E).

In contrast to the PDGFRα TKIs, FGFR inhibitor (BGJ398) treatment had no effect on AKT phosphorylation but instead decreased ERK1/2 phosphorylation ([Figure 3](#fig3){ref-type="fig"}H). As expected, BGJ398 had no effects on PDGFRα phosphorylation ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Correspondingly, combined treatment with PDGFRα and FGFR TKIs or ponatinib resulted in the suppression of both ERK1/2 and AKT phosphorylation ([Figure 3](#fig3){ref-type="fig"}H), consistent with a model where inhibition of both pathways is required for inducing apoptosis in MRT cells. To test this hypothesis, we treated the A204 cells with the PI3K/mTOR inhibitor NVP-BEZ235, the MEK inhibitor trametinib, and a combination of both inhibitors to block the AKT and ERK1/2 pathways, respectively. Immunoblotting confirmed that these pathways were suppressed upon inhibitor treatment ([Figure 3](#fig3){ref-type="fig"}I). Similar to PDGFRα inhibitor monotherapy ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A), treatment with BEZ235 alone led to a decrease in cell viability ([Figure 3](#fig3){ref-type="fig"}J) but had limited effects on apoptosis ([Figure 3](#fig3){ref-type="fig"}K). Treatment with trametinib alone was ineffective in reducing cell viability ([Figure 3](#fig3){ref-type="fig"}I), which is consistent with FGFR inhibitor monotherapy data ([Figure 3](#fig3){ref-type="fig"}A). Combined treatment of BEZ235 and trametinib recapitulates the elevated apoptosis levels ([Figure 3](#fig3){ref-type="fig"}K) observed with ponatinib or PDGFRα and FGFR inhibitor combinations ([Figures 3](#fig3){ref-type="fig"}D and 3G). Collectively our data provide additional support that MRTs cells require both the AKT and ERK1/2 pathways for cell survival.

FGFR Inhibitors Sensitize MRT Cells that Have Acquired Resistance to Pazopanib {#sec2.5}
------------------------------------------------------------------------------

Given that pazopanib is approved for soft tissue malignancies and there is currently no effective means to treat patients whose tumors have progressed on this TKI, we investigated if targeting FGFR1 is capable of sensitizing cells that have acquired pazopanib resistance. The resistant sublines maintain FGFR1 expression ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and activation loop phosphorylation ([Figure 2](#fig2){ref-type="fig"}C) at levels similar to the parental cells. Treating PazR cells with BGJ398 led to a reduction in cell viability that was not enhanced by the addition of pazopanib, demonstrating that these cells are no longer addicted to PDGFRα ([Figure 3](#fig3){ref-type="fig"}L; [Table S2](#mmc1){ref-type="supplementary-material"}). The degree of sensitization of the PazR cells in response to BGJ398 was similar to the IC~50~ of pazopanib treatment in the parental A204 cells ([Table S1](#mmc1){ref-type="supplementary-material"}). Pazopanib alone had no effect on apoptosis compared to vehicle control, while BGJ398, ponatinib, or the combination of BGJ398 and pazopanib led to a significant increase in the proportion of apoptotic cells ([Figure 3](#fig3){ref-type="fig"}M). These data demonstrate that FGFR1 blockade is an effective means of overcoming resistance to pazopanib.

Since the AKT pathway is inhibited by pazopanib via PDGFRα blockade ([Figure 3](#fig3){ref-type="fig"}H), we sought to determine if bypass of the requirement for the AKT pathway is a potential mechanism of pazopanib resistance. In the absence of pazopanib, PazR cells maintained a reduced level of AKT phosphorylation (compared to parental A204 cells), which decreased upon treatment with pazopanib, while FGFR1 blockade did not reduce AKT phosphorylation levels ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Treatment of PazR cells with BEZ235 abolished AKT phosphorylation ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Dose-response measurements showed that PazR cells were more resistant to BEZ235 treatment compared with parental A204 cells, with a \>3-fold increase in IC~50~ values ([Figure S3](#mmc1){ref-type="supplementary-material"}D). In addition, BEZ235 treatment in PazR cells did not lead to a statistically significant increase in apoptosis levels compared to parental A204 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}E). These data demonstrate that one potential mechanism of pazopanib resistance in the PazR cells is a reduced requirement for the AKT pathway for cell survival.

In some cancers, subpopulations of cancer cells display mutually exclusive RTK amplification events reflecting intratumoral heterogeneity, and clonal selection during therapy leads to acquired resistance ([@bib23]). Previous fluorescence in situ hybridization (FISH) analysis of A204 cells found that PDGFRα was not amplified at the genomic level ([@bib20]). To establish if heterogeneity in RTK expression could be a potential mechanism for drug resistance, immunofluorescence was performed to determine the distribution of PDGFRα and FGFR1. We found that both RTKs were expressed in all cells within the parental A204 population ([Figure S3](#mmc1){ref-type="supplementary-material"}F), and, consistent with the immunoblot data, the three resistant sublines displayed reduced PDGFRα levels and maintained FGFR1 expression. These data confirm that RTK expression is not mutually exclusive in distinct subpopulations, and they suggest that acquired resistance is unlikely the result of clonal selection of a pre-existing PDGFRα-deficient subpopulation but rather the consequence of genetic evolution by PDGFRα loss in drug-tolerant cells during TKI selection ([@bib8]).

PDGFRA and FGFR1 Are Expressed in Rhabdoid Tumor Patients {#sec2.6}
---------------------------------------------------------

To verify the clinical relevance of our findings, we evaluated the mRNA levels of *PDGFRA* and *FGFR1* in an RNA sequencing (RNA-seq) dataset of 23 primary rhabdoid tumor (RT) patient specimens composed of 12 MRTs and 11 AT/RTs. RNA-seq data from 172 normal tissue samples from the Illumina Bodymap were used as controls. Read count data in RT samples showed an average of 2,514 and 12,127 normalized reads mapped to *PDGFRA* and *FGFR1*, respectively, indicating moderate-high expression of each gene. Average levels of expression were significantly higher in RT than in the normal tissue collection for *PDGFRA* (p = 0.016) and *FGFR1* (p \< 0.001). Indeed, a substantial number of RT samples (35% and 70% of primary RT samples for *PDGFRA* and *FGFR1*, respectively) showed greater expression than the 95^th^ percentile of normal tissue samples for these genes, implying a large degree of tumorigenic overexpression ([Figure 4](#fig4){ref-type="fig"}A; [Table S3](#mmc2){ref-type="supplementary-material"}).

Immunohistochemistry was performed on two MRT and two AT/RT cases to determine PDGFRα and FGFR1 protein expression levels ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}). All cases showed no nuclear staining for SMARCB1. FGFR1 stained positively in the cytoplasm in three of four cases, and in both MRT specimens (NMB957 and NMB997) additional membrane staining was observed. PDGFRα was expressed in all four RT cases with cytoplasmic staining in tumor cells. As a comparison, we assessed two medulloblastoma cases (NMB361 and NMB795), which showed nuclear staining for SMARCB1 and were negative for both PDGFRα and FGFR1 ([Figure 4](#fig4){ref-type="fig"}B). These findings support the RNA-seq analysis and confirm that both PDGFRα and FGFR1 are expressed in RT patient specimens.

Discussion {#sec3}
==========

MRTs are often lethal within the first year of diagnosis and many patients are refractory to standard chemotherapy ([@bib18]). There is thus an urgent need for new effective therapies. This study demonstrates that dual inhibition of PDGFRα and FGFR1 leads to suppression of AKT and ERK1/2 phosphorylation, resulting in synergistic cytotoxicity in MRT cells. Previous reports have found that A204 cells are sensitive to sunitinib and dasatinib (albeit mislabeled as a rhabdomyosarcoma line) through the inhibition of PDGFRα ([@bib2], [@bib20]). The FGFR inhibitor BGJ398 also has been shown to reduce MRT cell growth ([@bib27]). However, our experiments find that these inhibitors have limited utility as single agents and do not induce apoptosis. Dual blockade of both RTKs promotes cytotoxicity across all drug doses tested in A204 and G402 cells. While TKI combinations may display better efficacy, there is a risk of greater toxicities. We show that ponatinib, a dual PDGFRα and FGFR1 inhibitor, induces apoptosis in MRT cells as a single agent. Given that our data document the expression of both PDGFRα and FGFR1 in RT patient specimens, we posit that ponatinib is a candidate for further evaluation in the treatment of RT patients. It should be noted that additional pre-clinical work in in vivo models is required to determine the therapeutic window of ponatinib or dual inhibition of PDGFRα and FGFR1 in order to take this therapeutic strategy further into clinical trials.

Our findings have implications for other cancer types that harbor SMARCB1 deficiencies, including epithelioid sarcomas, renal medullary carcinoma, epithelioid malignant peripheral nerve sheath tumors, and extraskeletal myxoid chondrosarcomas ([@bib19]). The SS18-SSX fusion in synovial sarcoma is known to disrupt the SWI/SNF assembly, resulting in SMARCB1-deficient complexes ([@bib12]). Furthermore, reduced SMARCB1 protein expression is found in a proportion of synovial sarcomas ([@bib19]). Our data indicate that it may be beneficial to assess PDGFRα and FGFR1 levels to determine if ponatinib has similar efficacy in these cancers.

Mutations in SWI/SNF subunits are found in ∼20% of cancers ([@bib13]). It was reported recently that EGFR expression is regulated by SMARCE1, SMARCA4, and ARID1A and that SMARCE1 deficiency confers TKI resistance in lung cancer ([@bib21]). [@bib27] showed that FGFR1 is upregulated when SMARCB1 is deleted in MRT cells, while [@bib4] recently demonstrated that EGFR expression is regulated by SMARCB1. In our experiments, ectopic expression of SMARCB1 in MRT cells show that FGFR1 and EGFR are only regulated by SMARCB1 in the A204 cells and not the G402 line ([Figure S2](#mmc1){ref-type="supplementary-material"}G), suggesting that there may be some context specificity associated with the regulation of RTK expression levels by SMARCB1. By showing that SMARCB1 loss also regulates PDGFRα expression levels, our study provides further evidence that exploiting RTK dependencies in cancers driven by SWI/SNF deficiencies is an effective therapeutic strategy in vitro. Since it is currently not possible to directly target the SWI/SNF complex, TKI combinations may have broader clinical utility in the treatment of this class of cancers.

Acquired resistance and tumor recurrence is common in patients undergoing TKI therapy. Pazopanib is approved for sarcoma treatment, but patients eventually develop resistance by mechanisms that are unknown ([@bib14]). Our study presents one mechanism of acquired resistance to pazopanib in soft tissue malignancies through PDGFRα loss and bypass of the AKT-signaling pathway, and it provides a means to overcome this resistance via FGFR1 blockade in vitro. Since it is less likely for cancer cells to develop acquired resistance when multiple RTKs are simultaneously inhibited up front, there is a rationale for using the PDGFRα and FGFR1 inhibitor combination as first-line therapy ([@bib25]). Indeed, attempts by our laboratory to generate acquired resistant lines to the PDGFRα and FGFR inhibitor combination have been unsuccessful ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Determination of FGFR1 levels in patients who develop resistance to pazopanib may stratify cases that could benefit from subsequent therapy with FGFR inhibitors. There remain several outstanding questions that need to be addressed in future studies, such as specifically how PDGFRα is downregulated in the PazR cells and what the mechanism is by which FGFR1 blockade overcomes resistance. Phosphoproteomic analysis of the PazR cells revealed candidate pathways such as PLCG1 and Src family kinases (YES1, FYN, and FGR), which are upregulated. These proteins serve as targets for future evaluation as additional means to overcome acquired pazopanib resistance.

In summary, we show that MRTs are exquisitely sensitive to the combined inhibition of PDGFRα and FGFR1 and that ponatinib is effective as a single agent in this disease in the in vitro setting. A previous chemical inhibitor screen in AT/RT cell lines found that the PDGFRα and FGFR inhibitors were not effective in reducing cell viability ([@bib22]), highlighting the complexity of cell-type-specific signaling dependencies in SMARCB1-deficient cell lines. Given the recent identification of distinct epigenetic subgroups in AT/RTs ([@bib11]), future work will need to establish if PDGFRα and FGFR dependencies are linked to specific molecular subgroups in SMARCB1-deficient tumors. We also find that treatment with FGFR inhibitors sensitizes MRT cells that have acquired resistance to pazopanib. This study provides proof-of-principle that exploiting RTK co-activation dependencies may have utility in the treatment of cancers with deficiencies in SWI/SNF subunits.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

A204, G402, and G401 cells were obtained from ATCC. CHLA226 and BT12 cells were provided by the Children's Oncology Group Cell Culture Repository. All other lines were a gift from Dr. Janet Shipley. Details for cell culture conditions and derivation of acquired resistant sublines are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Molecular Biology and Lentiviral Infection {#sec4.2}
------------------------------------------

The procedure for ectopic expression of SMARCB1 by lentiviral infection is detailed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Immunoblotting, Immunoprecipitation, and Immunofluorescence {#sec4.3}
-----------------------------------------------------------

After the indicated treatments, cells were lysed in radio-immunoprecipitation assay (RIPA) lysis buffer at 4°C. Lysates were loaded onto SDS-PAGE gels followed by blotting onto polyvinylidene fluoride (PVDF) membranes. Details of antibodies and immunoprecipitation and immunofluorescence analyses are presented in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Viability and Apoptosis Assays {#sec4.4}
-----------------------------------

Cells (2,000/well) were seeded in a 96-well plate, and they were treated with inhibitors at the indicated dose and combinations for 24 hr for apoptosis measurement by Caspase-Glo 3/7 Assay (Promega) or for 72 hr in cell viability measurements by WST-1 (Abcam), following the manufacturer's recommendations. IC~50~ data were generated from dose-response curves fitted using a four-parameter regression fit in PRISM 5 software (GraphPad). Details for annexin V staining and siRNA transfections are given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

aCGH, Gene Expression, and Phosphoproteomic Analysis {#sec4.5}
----------------------------------------------------

Genomic DNA was extracted and analyzed on an in-house aCGH platform consisting of ∼32,000 bacterial artificial clones (BACs) tiled across the genome. Descriptions of platform and data analysis procedure are provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. RNA was extracted and gene expression analysis was performed on Illumina HTv12 chip as per the manufacturer's recommendations. Data analysis methodology is presented in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Phosphoproteomic analysis was performed as described ([@bib10]), with the modifications in protocol and bioinformatic analysis as detailed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA-Seq and Immunohistochemistry of Patient Specimens {#sec4.6}
-----------------------------------------------------

Human tumor samples were provided by the UK CCLG as part of CCLG-approved biological study (2012 BS 05). Informed consent was obtained from all subjects. Human tumor investigations were conducted with approval from Newcastle/North Tyneside Research Ethics Committee (study reference 07/Q0905/71). RNA was extracted from 23 fresh frozen tumor tissue samples taken from pediatric patients with a confirmed diagnosis of *SMARCB1* negative RT. A paired-end cDNA sequencing library was created and sequenced on an Illumina Hi-Seq2500 to give ∼90 M paired-end reads. Reads were quality checked, aligned, and normalized gene counts were generated using Gencodev19 Transcriptome library. Variance stabilizing transformations of normalized counts were used as a measure of gene expression (full details are given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). RNA-seq data from normal tissues were taken from Illumina Bodymap (ArrayExpress: [E-MTAB-513](array-express:E-MTAB-513){#intref0010} and [E-MTAB-2836](array-express:E-MTAB-2836){#intref0015}). Full details for immunohistochemistry analysis are provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Methods {#sec4.7}
-------------------

Experimental results are representative of at least three independent experiments. The statistical significance of data in all figures was evaluated by Student's t test. Statistical analysis between combination and single treatment ([Figure 3](#fig3){ref-type="fig"}D) was done by ANOVA with Tukey's multiple comparison test. Calculations were performed with GraphPad Prism software.
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![MRT Cell Lines Are Sensitive to PDGFRα Inhibitors\
(A) Dose-response curves of dasatinib-, pazopanib-, and sunitinib-resistant (black) and -sensitive (red) cell lines. A panel of 14 cell lines was treated with a range of drug concentrations to determine IC~50~ values ([Table S1](#mmc1){ref-type="supplementary-material"}). Cell viability is normalized to DMSO control (n = 2 or 3).\
(B) Dose-response curves of TKI-resistant sublines (black) and parental A204 cells (red). IC~50~ values are detailed in [Table S1](#mmc1){ref-type="supplementary-material"}. Cell viability is normalized to DMSO control (n = 3).\
(C) Target selectivity overlap plot of dasatinib, pazopanib, and sunitinib shows that KIT, CSF1R, and PDGFRα are common targets.\
(D) Immunoblot of PDGFRα expression in parental A204 and resistant sublines is shown. DasR, dasatinib resistant; PazR, pazopanib resistant; SunR, sunitinib resistant.\
(E) Immunoprecipitation of PDGFRα followed by immunoblotting with phosphotyrosine-specific antibody (PY1000) shows a decrease in receptor phosphorylation with 1 μM TKI for 1 hr.\
(F) Immunoblot of PDGFRα expression in the MRT cells under mock, non-targeting control siCONT and siPDGFRα pool transfection conditions is shown.\
(G) Bar plots showing cell viability of MRT cells upon siRNA silencing of PDGFRα. Cell viability data are normalized to mock transfection (n = 3). Statistical analysis of siPDGFRα versus siCONT was performed by paired Student's t test (^∗^p \< 0.05).\
(H) Immunoblot of AKT and ERK1/2 phosphorylation levels in A204 cells treated with TKIs at the indicated doses for 3 hr is shown.\
(I) Immunoblot of PDGFRα shows downregulation of receptor levels upon ectopic SMARCB1 expression.\
For (A), (B), and (G), all values are mean ± SD.](gr1){#fig1}

![Molecular Profiling of A204 Cells\
(A) aCGH plots of A204 parental and resistant cells. Selected profiles of chromosome 22 illustrate focal deletion of SMARCB1 in 22q11.23. DasR harbors chromosome 17 and 13 alterations, illustrating gains (green) and losses (red), respectively. Full genomic profiles are presented in [Figure S1](#mmc1){ref-type="supplementary-material"}A.\
(B) Heatmap of the top 50 downregulated genes in the resistant sublines versus the parental A204 cells treated with TKIs. Full gene expression dataset is presented in [Figure S1](#mmc1){ref-type="supplementary-material"}B.\
(C) Heatmap of phosphoproteomic data with log~2~ fold change of untreated A204 parental cells versus DasR or PazR in the presence of TKI versus with PDGFRα and FGFR1 phosphorylation sites highlighted in red and blue, respectively. Gray boxes represent phosphosites that were not observed under that specific condition. Data presented are an average of three independent experiments.](gr2){#fig2}

![Dual Inhibition of PDGFRα and FGFR1 Is Cytotoxic in MRT Cells\
(A) Dose-response curves for MRT and AN3CA cell lines upon treatment with FGFR inhibitors BGJ398 and AZD4547. Cell viability is normalized to DMSO control (n = 3).\
(B) Immunoblot of FGFR1 expression in MRT cells under mock, non-targeting control siCONT and siFGFR1 pool transfection conditions is shown.\
(C) Bar plots showing cell viability of MRT cells upon siRNA silencing of FGFR1. Cell viability data are normalized to mock transfection (n = 3). Statistical analysis of siFGFR1 versus siCONT was performed by paired Student's t test (^∗∗^p \< 0.01; NS, not significant).\
(D) Bar plots showing the normalized fold change in caspase 3/7 activity in the A204 cells treated with PDGFRα and FGFR inhibitors or a combination at the indicated doses (n = 3). Data for G402 cells are presented in [Figure S2](#mmc1){ref-type="supplementary-material"}B. Data are normalized to DMSO control. Statistical analysis between combination and single TKI treatment was done by ANOVA with Tukey's multiple comparison test (^∗∗∗^p \< 0.001).\
(E) Combination index (CI) measurements for BGJ398 and PDGFRα inhibitors in A204 cells show synergy (CI \< 1) across all doses tested. Individual dose-response measurements are presented in [Figure S2](#mmc1){ref-type="supplementary-material"}D.\
(F) Log~2~ IC~50~ values of SMARCB1-deficient (n = 5) versus wild-type (n = 12) cell lines in response to ponatinib treatment. A panel of 17 cell lines was treated with a range of ponatinib concentrations. Cell viability is normalized to DMSO control (n = 2). Statistical analysis was performed by paired Student's t test.\
(G) Bar plots showing the normalized fold change in caspase 3/7 activity in the A204 and G402 cells treated with ponatinib (n = 3). Data are normalized to DMSO control. Statistical analysis was performed by paired Student's t test (^∗^p \< 0.05).\
(H) Immunoblot of AKT and ERK1/2 phosphorylation levels in A204 cells upon drug treatment with TKI at the 1 μM dose for 1 hr is shown.\
(I) Immunoblot of AKT and ERK1/2 phosphorylation levels in A204 cells upon drug treatment with BEZ235 and trametinib at the 1 μM dose for 1 hr is shown.\
(J) Dose-response curves for A204 cells treated with BEZ235, trametinib, and a combination of both. Cell viability is normalized to DMSO control (n = 3).\
(K) Bar plots showing the normalized fold change in caspase 3/7 activity in the A204 cells treated with BEZ235, trametinib, or a combination at the indicated doses (n = 3). Statistical analysis between combination and single kinase inhibitor treatment was performed by paired Student's t test (^∗^p \< 0.05 and ^∗∗^p \< 0.01).\
(L) Dose-response curves for PazR cells treated with pazopanib, BGJ398, a combination of both, or ponatinib. Cell viability is normalized to DMSO control (n = 3). IC~50~ values are detailed in [Table S2](#mmc1){ref-type="supplementary-material"}.\
(M) Bar plots showing percentage of annexin V staining in PazR cells treated with pazopanib, BGJ398, a combination of both inhibitors, or ponatinib (n = 3). Statistical analysis of TKI treatment versus DMSO was done by paired Student's t test (^∗^p \< 0.05 and ^∗∗^p \< 0.01; NS, not significant).\
Data presented for (A), (C), (D), (F), (G), (J), (K), (L), and (M) are means ± SD.](gr3){#fig3}

![PDGFRα and FGFR1 Are Expressed in Rhabdoid Tumor Patient Specimens\
(A) Relative RNA expression levels of *PDGFRA* and *FGFR1* genes between rhabdoid tumors (RTs) and various normal tissues. Boxplots show log2 variance-stabilized transformed expression across the samples. Boxplots show median score (thick black line), interquartile ranges (extent of box), and range (whiskers). Boxplots are ordered according to median expression level and RT is highlighted in red. The p values indicate one-sided t test between RT and normal tissues. The horizontal line represents the 95^th^ percentile of all normal tissues for each gene. RNA expression data are provided in [Table S3](#mmc2){ref-type="supplementary-material"}.\
(B) Immunohistochemical analysis of MRT and medulloblastoma (MB) patient specimens for H&E, anti-SMARCB1, anti-PDGFRα, and anti-FGFR1 staining. Scale bar represents 0.2 mm.](gr4){#fig4}
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